Multiple cancer-related proteins – in silico docking only

The term Multiple cancer-related proteins – in silico docking only is a descriptive label used in computational pharmacology and bioinformatics rather than a reference to a specific biological target. It signifies that a study or dataset involves the virtual screening of compounds against a diverse array of protein structures known to play roles in cancer progression, such as kinases, growth factor receptors, or enzymes (Kitchen et al., 2004, Nature Reviews Drug Discovery). This approach is typically employed in early-stage drug discovery to identify lead compounds with potential polypharmacological profiles or to explore binding affinities across multiple structural templates (Lionta et al., 2014, Current Pharmaceutical Design). Because this designation encompasses a heterogeneous group of molecules rather than a single molecular entity, it does not possess a singular biological function, molecular classification, or defined mechanism of action. In the context of therapeutic development and database curation, this entry is considered incorrect or overly broad as it fails to specify the actual molecular targets being modulated (Forli et al., 2016, Nature Protocols).

Not applicable as this refers to a computational methodology involving various proteins.